University of tx health
Baptist medical center
Christus santa rosa childrens hospital
Methodist willowbrook hospital
Metropolitan methodist hospital
Nix health care system
North central baptist hospital
Northeast baptist hospital
Southeast baptist hospital
St lukes baptist hospital
University health system
UT Medicine San Antonio
Christus Santa Rosa Hospital
Ctrc@Ut Health Science Center
Veterans Administration Hospital
Christus Santa Rosa
A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
Cancer Chemother. Pharmacol., Feb;59(2):165-74 (2007)
Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors.
Clin. Cancer Res., Sep;12(17):5207-15 (2006)
Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics.
Clin. Cancer Res., Aug;14(16):5000-5 (2008)
Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation.
J. Cell. Mol. Med., Oct;14(10):2448-59 (2010)
Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels.
Clin. Cancer Res., Jan;16(1):141-53 (2010)
Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors.
Clin. Cancer Res., Jun;16(11):3044-56 (2010)
A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer.
Cancer Chemother. Pharmacol., Apr;67(4):751-64 (2011)
Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin.
Clin. Cancer Res., Jan;17(2):363-71 (2011)
Clinical activity of mammalian target of rapamycin inhibitors in solid tumors.
Target Oncol., Jun;6(2):69-94 (2011)
Development of rationally designed, target-based agents for the treatment of advanced colorectal cancer.
Clin Colorectal Cancer., Jul;4(2):107-23 (2004)
Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.
J. Clin. Oncol., Feb;24(4):552-62 (2006)
Heat shock proteins: a potential anticancer target.
Curr Drug Targets., Dec;12(14):2001-8 (2011)
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.
J. Clin. Oncol., Jan;26(3):361-7 (2008)
Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
Cancer Chemother. Pharmacol., May;63(6):1065-71 (2009)